N※N

Thermo Fisher Opens Bioprocess Design Centre in Hyderabad to Accelerate India's Biopharma Growth

90

  //science-technology.news-articles.net/content/2 .. abad-to-accelerate-india-s-biopharma-growth.html
  Published in Science and Technology on Tuesday, November 25th 2025 at 23:26 GMT by The Hans India

• 🞛 This publication is a summary or evaluation of another publication
• 🞛 This publication contains editorial commentary or bias from the source

2025-11-25 224 x 224 / 8556 Bytes

2025-11-25 179 x 224 / 5208 Bytes

2025-11-25 224 x 224 / 9435 Bytes

2025-11-25 224 x 224 / 5181 Bytes

Thermo Fisher Scientific Opens a Bioprocess Design Centre in Hyderabad to Accelerate India’s Biopharma Growth

Thermo Fisher Scientific, a global leader in life‑science research and biopharmaceutical manufacturing, has announced the opening of its first dedicated bioprocess design centre in Hyderabad, India. The move is part of the company’s strategy to deepen its footprint in the country’s rapidly expanding biopharma sector and to provide end‑to‑end support to Indian companies that are looking to develop, scale‑up, and commercialise biotherapeutics, including vaccines, biosimilars, and cell‑based products.

Why Hyderabad?

Hyderabad has emerged as one of India’s premier biotech hubs, hosting a growing number of research institutes, startups, and contract manufacturing organisations (CMOs). The city benefits from a strong ecosystem of universities, such as the Indian Institute of Technology (IIT) Hyderabad, and a sizeable talent pool in biotechnology and engineering. Thermo Fisher noted that establishing a presence in the city allows the company to tap into this talent base and to work closely with local companies that are increasingly moving their product development activities to India.

Scope of the Centre

The new centre is designed to offer a full spectrum of bioprocess development services. These include:

• Process Design & Scale‑up – Thermo Fisher’s team will work with clients to design robust production processes that can be scaled from laboratory to production scale while maintaining product quality and compliance with regulatory standards.
• Analytics & Monitoring – The facility will house state‑of‑the‑art analytical equipment, enabling real‑time monitoring of critical process parameters. This aligns with the company’s focus on Process Analytical Technology (PAT), a cornerstone of modern bioprocessing.
• Regulatory Support – From early‑stage development to regulatory submissions, Thermo Fisher will help companies navigate the complex regulatory landscape in India and abroad, drawing on its global experience in filing with agencies such as the FDA and the EMA.
• Technology Transfer & Training – The centre will also offer training programmes and technology transfer services, helping local teams adopt best practices in bioprocess design.

The infrastructure includes a dedicated lab space, a small‑scale bioreactor suite, and advanced analytical instrumentation, such as chromatography systems and mass spectrometers. While the initial focus is on small‑ to medium‑scale projects, Thermo Fisher indicated that the centre could be expanded to support larger manufacturing runs in the future.

Thermo Fisher’s Expertise

Thermo Fisher’s bioprocessing portfolio is built on decades of research and a portfolio of patented technologies. The company’s expertise spans:

• Design of Experiments (DoE) – Structured experimental designs help identify key variables that influence yield, purity, and product stability.
• Micro‑ and Macro‑Bioreactors – Thermo Fisher’s range of bioreactors caters to diverse cell lines, offering flexibility for mammalian, microbial, and cell‑based therapies.
• Quality‑by‑Design (QbD) – The centre will adopt QbD principles to embed quality into the process from the outset, thereby reducing risk and speeding up time‑to‑market.

“India’s biotech sector is on the cusp of a major transformation,” said Dr. Anil Kumar, Head of Thermo Fisher’s India business. “By bringing our world‑class bioprocessing expertise to Hyderabad, we aim to support local companies in producing safe, effective, and affordable biotherapeutics that can reach patients worldwide.”

Target Clients

Thermo Fisher intends to serve a wide range of stakeholders:

• Biopharma Startups – Many emerging companies need help translating laboratory discoveries into scalable processes.
• Contract Manufacturing Organisations (CMOs) – CMOs that outsource process development can use the centre to accelerate project timelines.
• Academic and Research Institutes – These organisations can leverage Thermo Fisher’s technologies to bridge the gap between discovery and production.
• Large Pharma Companies – Multinationals looking to establish or expand their Indian manufacturing footprint will find value in the centre’s regulatory support and process optimization services.

Collaborations and Ecosystem Impact

The centre is expected to forge partnerships with local universities and research institutes. By collaborating with IIT Hyderabad and the National Institute of Biomedical Engineering, the facility can provide access to cutting‑edge research and a pipeline of skilled graduates. The presence of Thermo Fisher in Hyderabad is also anticipated to stimulate job creation—not just directly within the centre but indirectly through increased demand for support services, such as logistics and regulatory consulting.

Industry analysts predict that India could become a global hub for biologics manufacturing by 2030. Thermo Fisher’s move is seen as a timely investment that dovetails with government initiatives such as the “Biotech and Life Sciences Cluster” program, which offers incentives to companies investing in biotech infrastructure.

Broader Context

India’s biopharma market has experienced double‑digit growth over the past decade, driven by rising demand for biologics and the need for affordable biosimilars. The COVID‑19 pandemic further highlighted the importance of local manufacturing capacity, especially for vaccines and therapeutics. Thermo Fisher’s centre comes at a juncture when companies are eager to adopt advanced process technologies that reduce production costs while meeting stringent quality standards.

The company’s earlier initiatives—such as the launch of a biotechnology incubator in Bengaluru and a training programme in Pune—demonstrate its commitment to building a robust biotech ecosystem across the country. The Hyderabad centre is a natural extension of these efforts.

Looking Ahead

Thermo Fisher plans to expand its service offering over the next few years, with potential additions such as a dedicated facility for cell‑based therapies and a cloud‑based analytics platform for remote monitoring. The centre’s success will likely depend on the company’s ability to adapt to local regulatory nuances and to foster collaborative relationships with Indian biotech firms.

In summary, Thermo Fisher Scientific’s new bioprocess design centre in Hyderabad marks a significant step toward strengthening India’s position as a global biopharma manufacturing hub. By blending advanced technology, regulatory expertise, and a commitment to local partnerships, the centre aims to help Indian companies accelerate the development and production of life‑saving biotherapeutics.